R&D continues for medication to treat effects of nuclear blast
NEWS IN BRIEF — Posted Sept. 13, 2010
In an effort to be ready for a health emergency, the government awarded a California company a $153 million contract to continue developing a new way to treat an illness caused by exposure to high levels of ionizing radiation, the type generated from a nuclear blast.
The contract will allow Cellerant Therapeutics Inc., based in San Carlos, Calif., to continue developing a medication called CLT-008. The medication potentially could be used to treat neutropenia. It also potentially could be used for other blood disorders and complications of cancer, the Dept. of Health and Human Services' Biomedical Advanced Research and Development Authority said in its Sept. 1 announcement.
Note: This item originally appeared at http://www.ama-assn.org/amednews/2010/09/13/gvbf0913.htm.